Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Pembrolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma

NCT06006013 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT06006013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06006013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Pembrolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
January 15, 2025
Completion date
December 16, 2028
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal cortical carcinoma, locally advanced adrenal cortex carcinoma, stage iii adrenal cortex carcinoma, stage iv adrenal cortex carcinoma ajcc v8, unresectable adrenal cortex carcinoma